IL320576A - Oral formulation of n-pyridinyl acetamide derivative for treating interstitial lung disease - Google Patents
Oral formulation of n-pyridinyl acetamide derivative for treating interstitial lung diseaseInfo
- Publication number
- IL320576A IL320576A IL320576A IL32057625A IL320576A IL 320576 A IL320576 A IL 320576A IL 320576 A IL320576 A IL 320576A IL 32057625 A IL32057625 A IL 32057625A IL 320576 A IL320576 A IL 320576A
- Authority
- IL
- Israel
- Prior art keywords
- lung disease
- oral formulation
- interstitial lung
- acetamide derivative
- treating interstitial
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263382311P | 2022-11-04 | 2022-11-04 | |
| PCT/EP2023/080652 WO2024094844A1 (en) | 2022-11-04 | 2023-11-03 | Oral formulation of n-pyridinyl acetamide derivative for treating interstitial lung disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL320576A true IL320576A (en) | 2025-07-01 |
Family
ID=88689993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL320576A IL320576A (en) | 2022-11-04 | 2025-04-29 | Oral formulation of n-pyridinyl acetamide derivative for treating interstitial lung disease |
Country Status (14)
| Country | Link |
|---|---|
| JP (1) | JP2025536575A (en) |
| KR (1) | KR20250099240A (en) |
| CN (1) | CN120187430A (en) |
| AR (1) | AR130952A1 (en) |
| AU (1) | AU2023374727A1 (en) |
| CL (1) | CL2025001306A1 (en) |
| CO (1) | CO2025007400A2 (en) |
| CR (1) | CR20250229A (en) |
| DO (1) | DOP2025000103A (en) |
| IL (1) | IL320576A (en) |
| MX (1) | MX2025005174A (en) |
| PE (1) | PE20251575A1 (en) |
| TW (1) | TW202434248A (en) |
| WO (1) | WO2024094844A1 (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017007218B1 (en) | 2014-10-08 | 2023-10-10 | Redx Pharma Plc | N-PYRIDYL ACETAMIDE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS, PHARMACEUTICAL FORMULATIONS COMPRISING THE SAME AND THEIR USES |
-
2023
- 2023-11-03 CN CN202380078161.XA patent/CN120187430A/en active Pending
- 2023-11-03 WO PCT/EP2023/080652 patent/WO2024094844A1/en not_active Ceased
- 2023-11-03 TW TW112142363A patent/TW202434248A/en unknown
- 2023-11-03 AU AU2023374727A patent/AU2023374727A1/en active Pending
- 2023-11-03 CR CR20250229A patent/CR20250229A/en unknown
- 2023-11-03 JP JP2025524809A patent/JP2025536575A/en active Pending
- 2023-11-03 PE PE2025000928A patent/PE20251575A1/en unknown
- 2023-11-03 KR KR1020257018380A patent/KR20250099240A/en active Pending
- 2023-11-03 AR ARP230102947A patent/AR130952A1/en unknown
-
2025
- 2025-04-29 IL IL320576A patent/IL320576A/en unknown
- 2025-05-02 DO DO2025000103A patent/DOP2025000103A/en unknown
- 2025-05-02 CL CL2025001306A patent/CL2025001306A1/en unknown
- 2025-05-02 MX MX2025005174A patent/MX2025005174A/en unknown
- 2025-06-03 CO CONC2025/0007400A patent/CO2025007400A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202434248A (en) | 2024-09-01 |
| CR20250229A (en) | 2025-07-11 |
| DOP2025000103A (en) | 2025-06-15 |
| CL2025001306A1 (en) | 2025-08-01 |
| WO2024094844A1 (en) | 2024-05-10 |
| KR20250099240A (en) | 2025-07-01 |
| PE20251575A1 (en) | 2025-06-12 |
| CN120187430A (en) | 2025-06-20 |
| AR130952A1 (en) | 2025-02-05 |
| JP2025536575A (en) | 2025-11-07 |
| CO2025007400A2 (en) | 2025-06-16 |
| MX2025005174A (en) | 2025-06-02 |
| AU2023374727A1 (en) | 2025-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL299167A (en) | Compositions and methods for treatment of gene therapy patients | |
| EA202190544A1 (en) | APPLICATION OF RILUZOL TABLETS DISPOSING IN THE ORAL CAVITY FOR THE TREATMENT OF DISEASES | |
| AU2024216821A1 (en) | Rifabutin analogs for the treatment of bacterial diseases | |
| DK4426307T3 (en) | NEW ORAL PHARMACEUTICAL COMPOSITION AND DOSAGE SCHEDULE FOR THE TREATMENT OF PROGRESSIVE FIBROSITISING INTERSTITIAL LUNG DISEASES | |
| CA3263467A1 (en) | Compounds for treatment of conditions and diseases | |
| CA3266876A1 (en) | Rifabutin analogs for the treatment of disease | |
| CA3272254A1 (en) | Oral formulation of n-pyridinyl acetamide derivative for treating interstitial lung disease | |
| AU2024317483A1 (en) | Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease | |
| IL320242A (en) | Compounds and their use for treatment of hemoglobinopathies | |
| GB202313514D0 (en) | Treatment of inflammatory diseases | |
| GB202202761D0 (en) | Compositions for treatment of dental caries | |
| DOP2025000103A (en) | Oral formulation of N-pyridinylacetamide derivative for the treatment of interstitial lung disease | |
| EP4405469A4 (en) | COMPOSITIONS FOR THE TREATMENT OF CHARCOT-MARIE-TOOTH DISEASE | |
| HK40121149A (en) | Oral octreotide for treatment of disease | |
| PL4106783T3 (en) | Composition for the treatment of skin and mucous membrane diseases | |
| IL327399A (en) | Compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| GB202403324D0 (en) | Compounds for the treatment of skin diseases | |
| LT4648753T (en) | Compositions for the treatment of cftr-mediated diseases | |
| IL314586A (en) | Compositions and methods for improved treatment of pompe disease | |
| GB202315831D0 (en) | Treatment of skin disease | |
| GB202404416D0 (en) | Treatment of disease | |
| HK40105820A (en) | Methods and compositions for treatment of disease | |
| EP4304624A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES | |
| CA3297926A1 (en) | Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease | |
| CA3278922A1 (en) | Rifabutin analogs for the treatment of bacterial diseases |